Cutaneous T-cell lymphoma |
hsa-miR-200c |
HuT 78, MyLa |
Down |
JAGGED1 |
Overexpression of miR-200c suppresses the expression of Jagged1, associated with reduction of Notch1 levels in cutaneous T-cell lymphomas. |
Gallardo et al., 2015 |
T-cell acute lymphoblastic leukemia |
hsa-miR-150 |
MOLT-3, Jurkat, CCRF-HSB-2 |
Up |
NOTCH3 |
Overexpression of miR-150 downregulates the expression of NOTCH3 and has adverse effects on proliferation and survival T-cell acute lymphoblastic leukemia. |
Ghisi et al., 2011 |
T-cell acute lymphoblastic leukemia |
hsa-miR-451 |
T-ALL cell lines |
Down |
MYC |
hsa-miR-451 acts as a suppressor of tumor initiation by downregulating the expression of MYC in acute lymphoblastic leukemia. |
Li et al., 2011 |
Hepatitis C virus infection |
hsa-miR-449a |
Hep-G2 |
Down |
NOTCH1 |
MicroRNA-449a plays an important role in regulating the expression of YKL40 through down-regulating NOTCH1 which is the components of the NOTCH signaling pathway. |
Sarma et al., 2012 |
Gastric cancer |
hsa-miR-151 |
SC-M1, AGS, NUGC-3, SNU-16, AZ-521, KATO III |
Up |
P53 |
Notch1/miR-151-5p axis regulates the progression of gastric cancer cells through targeting p53. |
Hsu et al., 2016 |
Gastric signet ring cell carcinoma |
hsa-miR-935 |
GES-1, AGS, MKN28, MKN45, KATO III, SGC-7901 |
Down |
NOTCH1 |
MicroRNA-935 suppresses gastric carcinoma cell proliferation, migration and invasion by directly inhibiting the expression of Notch1. |
Yan et al., 2016 |
Gastric cancer |
hsa-miR-23b |
AGS, NUGC-3, SNU-16, SC-M1, AZ-521 |
Down |
N2IC |
miR-23b inhibits tumor progression and pluripotency gene expression in gastric cancer cells through suppressing Notch2 receptor. |
Huang et al., 2015 |
Gastric cancer |
hsa-miR-100 |
MGC-803, HGC-27, GES-1 |
Up |
HS3ST2 |
Antagonism of miR-100 enhances the expression level of HS3ST2, results in the activation of the Notch-apoptosis pathway in tumor cells. |
Yang et al., 2015 |
Osteosarcoma |
hsa-miR-26a |
Zos |
Down |
JAGGED1 |
Upregulation of miR-26a inhibits the expression of Jagged1, one of the Notch ligand. MicroRNA-26a functions as tumor suppressor via suppression of Jagged1/Notch signaling. |
Lu et al., 2016 |
Breast cancer |
hsa-miR-101 |
Breast |
Down |
EYA1 |
MicroRNA-101 suppresses cell proliferation and promote apoptosis in breast cancer by down-regulating EYA1 via the Notch signaling pathway. |
Guan et al., 2016 |
Triple negative breast cancer |
hsa-miR-9 |
MDA-MB-231 |
Up |
NOTCH1 |
MicroRNA-9 elicits a suppressor-like activity in metastatic breast cancer cells by targeting Notch1. |
Mohammadi-Yeganeh et al., 2015 |
Breast cancer |
hsa-miR-34a |
MCF-7 |
Down |
NOTCH1 |
MicroRNA-34a suppresses breast cancer stemness and enhances the chemosensitivity to paclitaxel by targeting the Notch1 pathway. |
Kang et al., 2015 |
Cervical cancer |
hsa-miR-34a |
HeLa, Ca Ski, SiHa |
Down |
NOTCH1 |
MicroRNA-34a suppresses invasiveness in cervical cancer through targeting the Notch pathway. |
Pang et al., 2010 |
Choriocarcinoma |
hsa-miR-34a |
BeWo, JAR |
Down |
NOTCH1 |
MicroRNA-34a suppresses invasiveness in choriocarcinoma through targeting the Notch pathway. |
Pang et al., 2010 |
Osteosarcoma |
hsa-miR-26a |
Bone |
Down |
JAGGED1 |
MicroRNA-26a suppresses stem cell-like phenotype and tumor growth of osteosarcoma by down-regulating Jagged1 expression. |
Lu et al., 2016 |